473 related articles for article (PubMed ID: 23082810)
1. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
Rustin MH
Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
[TBL] [Abstract][Full Text] [Related]
2. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
3. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
5. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
Tzu J; Kerdel F
Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
7. Biologic Therapy in Psoriasis: Safety Profile.
Campanati A; Ganzetti G; Giuliodori K; Molinelli E; Offidani A
Curr Drug Saf; 2016; 11(1):4-11. PubMed ID: 26463245
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
9. Advancements in the treatment of psoriasis: role of biologic agents.
Rich SJ; Bello-Quintero CE
J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
[TBL] [Abstract][Full Text] [Related]
10. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
11. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
Smith EC; Riddle C; Menter MA; Lebwohl M
Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
14. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
Papp KA; Dekoven J; Parsons L; Pirzada S; Robern M; Robertson L; Tan JK
J Cutan Med Surg; 2012; 16(3):153-68. PubMed ID: 22713438
[TBL] [Abstract][Full Text] [Related]
16. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab.
Papoutsaki M; Talamonti M; Giunta A; Costanzo A; Ruzzetti M; Teoli M; Chimenti S
Dermatology; 2010; 221 Suppl 1():43-7. PubMed ID: 20733314
[TBL] [Abstract][Full Text] [Related]
17. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for high-quality use of biologic therapies in adults with plaque psoriasis].
Marques Pinto G; Filipe P
Acta Med Port; 2012; 25(2):125-41. PubMed ID: 22985925
[TBL] [Abstract][Full Text] [Related]
19. Iatrogenic effects of biologics for psoriasis.
Stevenson ML; Lebwohl M
Clin Dermatol; 2011; 29(6):614-21. PubMed ID: 22014983
[TBL] [Abstract][Full Text] [Related]
20. Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?
Sterry W; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():9-16. PubMed ID: 22758912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
